No abstract available
MeSH terms
-
Adult
-
Age Distribution
-
Anti-HIV Agents / therapeutic use*
-
Communicable Disease Control / organization & administration*
-
Disease Management
-
Female
-
Hepatitis C / diagnosis
-
Hepatitis C / drug therapy*
-
Hepatitis C / epidemiology*
-
Hepatitis C / transmission
-
Hepatitis C, Chronic / diagnosis
-
Hepatitis C, Chronic / drug therapy
-
Hepatitis C, Chronic / epidemiology
-
Hepatitis C, Chronic / transmission
-
Heterocyclic Compounds, 3-Ring / adverse effects
-
Heterocyclic Compounds, 3-Ring / therapeutic use
-
Humans
-
Incidence
-
Liver Cirrhosis / prevention & control*
-
Liver Cirrhosis / virology
-
Male
-
Middle Aged
-
Needs Assessment
-
Prisoners / statistics & numerical data
-
Prisons*
-
Ribavirin / adverse effects
-
Ribavirin / therapeutic use
-
Risk Assessment
-
Sex Distribution
-
Simeprevir
-
Sofosbuvir
-
Sulfonamides / adverse effects
-
Sulfonamides / therapeutic use
-
Telemedicine / statistics & numerical data
-
Treatment Outcome
-
United States
-
Uridine Monophosphate / adverse effects
-
Uridine Monophosphate / analogs & derivatives
-
Uridine Monophosphate / therapeutic use
-
Young Adult
Substances
-
Anti-HIV Agents
-
Heterocyclic Compounds, 3-Ring
-
Sulfonamides
-
Ribavirin
-
Simeprevir
-
Uridine Monophosphate
-
Sofosbuvir